Cargando…

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma

BACKGROUND: We have previously discovered a relationship between the low expression of protein tyrosine phosphatase, receptor type O (PTPRO) in tumor-infiltrating T cells and immunosuppression. The aim of the present study was to investigate the relationship between decreased PTPRO and increased pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenjie, Liu, Yang, Yan, Zhongyi, Yang, Hui, Sun, Wei, Yao, Yongliang, Chen, Yun, Jiang, Runqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319788/
https://www.ncbi.nlm.nih.gov/pubmed/32581055
http://dx.doi.org/10.1136/jitc-2019-000285
_version_ 1783551116787580928
author Zhang, Wenjie
Liu, Yang
Yan, Zhongyi
Yang, Hui
Sun, Wei
Yao, Yongliang
Chen, Yun
Jiang, Runqiu
author_facet Zhang, Wenjie
Liu, Yang
Yan, Zhongyi
Yang, Hui
Sun, Wei
Yao, Yongliang
Chen, Yun
Jiang, Runqiu
author_sort Zhang, Wenjie
collection PubMed
description BACKGROUND: We have previously discovered a relationship between the low expression of protein tyrosine phosphatase, receptor type O (PTPRO) in tumor-infiltrating T cells and immunosuppression. The aim of the present study was to investigate the relationship between decreased PTPRO and increased programmed death ligand 1 (PD-L1) in both the peripheral monocytes and tumor-infiltrating macrophages of human hepatocellular carcinoma (HCC). METHODS: The expression and correlation of all the indices were explored in monocytes and tumor-infiltrating macrophages within both human and mice HCC. The mechanic regulations were studied by using both in vitro and in vivo studies. RESULTS: We found a significant decrease in PTPRO in HCC peripheral monocytes that was associated with increased PD-L1 expression in peripheral monocytes and tumor-associated macrophages (TAMs) in HCC. Monocyte PD-L1 and PTPRO therefore could serve as valuable prognostic indicators for post-surgery patients with HCC and were associated with increased T-cell exhaustion (Tim3+T cells). A depletion of PTPRO promoted PD-L1 secretion in both monocytes and macrophages through the JAK2/STAT1 and JAK2/STAT3/c-MYC pathways. Increased IL-6 expression was associated with activation of JAK2/STAT3/c-MYC and with decreased PTPRO expression through the STAT3/c-MYC/miR-25–3 p axis. Monocytes and TAMs showed significantly increased miR-25–3 p expression, which could target the 3′ untranslated region of PTPRO. The miR-25–3 p expression positively correlated with serum IL-6 levels, but inversely correlated with PTPRO in HCC monocytes. IL-6/STAT3/c-MYC activation enhanced in vitro miR-25–3 p transcription and decreased PTPRO, while further promoting PD-L1 secretion. Adoptive cell transfer of c-MYC/miR-25–3 p–modified monocytes promoted tumor growth by downregulating PTPRO and causing a PD-L1–induced immunosuppression in an orthotopic tumor transplantation model. CONCLUSIONS: Increased serum IL-6 downregulated PTPRO expression in HCC monocytes and macrophages by activating STAT3/c-MYC/miR-25–3 p and by further enhancing PD-L1 expression through JAK2/STAT1 and JAK2/STAT3/c-MYC signaling.
format Online
Article
Text
id pubmed-7319788
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73197882020-07-01 IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma Zhang, Wenjie Liu, Yang Yan, Zhongyi Yang, Hui Sun, Wei Yao, Yongliang Chen, Yun Jiang, Runqiu J Immunother Cancer Basic Tumor Immunology BACKGROUND: We have previously discovered a relationship between the low expression of protein tyrosine phosphatase, receptor type O (PTPRO) in tumor-infiltrating T cells and immunosuppression. The aim of the present study was to investigate the relationship between decreased PTPRO and increased programmed death ligand 1 (PD-L1) in both the peripheral monocytes and tumor-infiltrating macrophages of human hepatocellular carcinoma (HCC). METHODS: The expression and correlation of all the indices were explored in monocytes and tumor-infiltrating macrophages within both human and mice HCC. The mechanic regulations were studied by using both in vitro and in vivo studies. RESULTS: We found a significant decrease in PTPRO in HCC peripheral monocytes that was associated with increased PD-L1 expression in peripheral monocytes and tumor-associated macrophages (TAMs) in HCC. Monocyte PD-L1 and PTPRO therefore could serve as valuable prognostic indicators for post-surgery patients with HCC and were associated with increased T-cell exhaustion (Tim3+T cells). A depletion of PTPRO promoted PD-L1 secretion in both monocytes and macrophages through the JAK2/STAT1 and JAK2/STAT3/c-MYC pathways. Increased IL-6 expression was associated with activation of JAK2/STAT3/c-MYC and with decreased PTPRO expression through the STAT3/c-MYC/miR-25–3 p axis. Monocytes and TAMs showed significantly increased miR-25–3 p expression, which could target the 3′ untranslated region of PTPRO. The miR-25–3 p expression positively correlated with serum IL-6 levels, but inversely correlated with PTPRO in HCC monocytes. IL-6/STAT3/c-MYC activation enhanced in vitro miR-25–3 p transcription and decreased PTPRO, while further promoting PD-L1 secretion. Adoptive cell transfer of c-MYC/miR-25–3 p–modified monocytes promoted tumor growth by downregulating PTPRO and causing a PD-L1–induced immunosuppression in an orthotopic tumor transplantation model. CONCLUSIONS: Increased serum IL-6 downregulated PTPRO expression in HCC monocytes and macrophages by activating STAT3/c-MYC/miR-25–3 p and by further enhancing PD-L1 expression through JAK2/STAT1 and JAK2/STAT3/c-MYC signaling. BMJ Publishing Group 2020-06-24 /pmc/articles/PMC7319788/ /pubmed/32581055 http://dx.doi.org/10.1136/jitc-2019-000285 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Basic Tumor Immunology
Zhang, Wenjie
Liu, Yang
Yan, Zhongyi
Yang, Hui
Sun, Wei
Yao, Yongliang
Chen, Yun
Jiang, Runqiu
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
title IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
title_full IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
title_fullStr IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
title_full_unstemmed IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
title_short IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
title_sort il-6 promotes pd-l1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type o expression in human hepatocellular carcinoma
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319788/
https://www.ncbi.nlm.nih.gov/pubmed/32581055
http://dx.doi.org/10.1136/jitc-2019-000285
work_keys_str_mv AT zhangwenjie il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT liuyang il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT yanzhongyi il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT yanghui il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT sunwei il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT yaoyongliang il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT chenyun il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma
AT jiangrunqiu il6promotespdl1expressioninmonocytesandmacrophagesbydecreasingproteintyrosinephosphatasereceptortypeoexpressioninhumanhepatocellularcarcinoma